Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Receivables (2021 - 2025)

BridgeBio Pharma (BBIO) has disclosed Receivables for 4 consecutive years, with $139.4 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 2853.07% to $139.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $139.4 million through Dec 2025, up 2853.07% year-over-year, with the annual reading at $139.4 million for FY2025, 2853.07% up from the prior year.
  • Receivables hit $139.4 million in Q4 2025 for BridgeBio Pharma, up from $116.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $139.4 million in Q4 2025 to a low of $2.4 million in Q4 2023.
  • Historically, Receivables has averaged $66.5 million across 4 years, with a median of $76.9 million in 2025.
  • Biggest five-year swings in Receivables: skyrocketed 100.85% in 2024 and later soared 2853.07% in 2025.
  • Year by year, Receivables stood at $10.2 million in 2021, then plummeted by 76.89% to $2.4 million in 2023, then surged by 100.85% to $4.7 million in 2024, then skyrocketed by 2853.07% to $139.4 million in 2025.
  • Business Quant data shows Receivables for BBIO at $139.4 million in Q4 2025, $116.5 million in Q3 2025, and $76.9 million in Q2 2025.